Market Overview:
The global CAR-T cellular immunotherapy drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of cancer, technological advancements in CAR-T therapies, and rising investments by pharmaceutical companies in this field. The global CAR-T cellular immunotherapy drug market is segmented on the basis of type into CD19-targeted and BCMA-targeted therapies. The CD19-targeted therapy segment is expected to account for the majority share of the global CAR-T cellular immunotherapy drug market during the forecast period. This can be attributed to factors such as increasing adoption of these therapies for treatment of multiple myeloma and non-Hodgkin lymphoma. On the basis of application, the global CAR T cell therapy drugs market is segmented into multiple myeloma, non Hodgkin lymphoma, leukemia and other applications. The multiple myeloma segment is expected to account for a major share of this market duringthe forecast period owingto high prevalenceof this diseaseand growing adoptionofCAR Tcelltherapiesfor itstreatment .
Product Definition:
CAR-T cellular immunotherapy drug is a new type of cancer treatment that uses a patient's own immune cells to fight cancer. The cells, called T cells, are removed from the patient's blood and genetically modified in the lab to make them better at attacking cancer. They are then infused back into the patient's body.
CD19-Targeted:
The global CD19-Targeted, it's usage and growth factor in CAR-T cellular immunotherapy drug market size was valued at USD 1.8 billion in 2018 and is expected to grow at a compound annual growth rate (CAGR) of 20.7% from 2019 to 2027.
BCMA-Targeted:
BCMA-Targeted and its usage in CAR-T cellular immunotherapy drug market is expected to witness significant growth over the forecast period. The BCMA (Bcr-A1) targeted therapy has shown great results in patients with relapsed or refractory (R/R) large B cell lymphoma, as well as R/R follicular lymphoma.
Application Insights:
The multiple myeloma segment dominated the global market in terms of revenue share in 2017. This is owing to the increasing prevalence of this disease and its growing treatment rate with autologous stem cell transplantation. Moreover, there are several ongoing clinical trials for new drugs for multiple myeloma which is expected to propel the growth of this segment during the forecast period.
Non-hodgkin lymphoma held a significant share as well as it was valued at USD 142.0 million in 2017 due to an increase in incidence rates and approvals/treatments pertaining to new molecular entities from 2018 till date.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, increased funding for research and development, and high adoption of this therapy. In addition, increasing incidence of cancer is also one of the major factors responsible for its largest share. According to statistics from American Cancer Society Inc., approximately 2 million new cases were estimated to be diagnosed in 2019 in U.S., with most cancers (60%) being attributed to lifestyle factors such as smoking or obesity rather than genetic mutations alone (CDC).
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising number immunotherapy trials conducted there along with growing target population base that requires treatment for various diseases. For instance, Novartis AG & Co.; KKH Holdings Berhad; Samsung Biologics; Roche Ltd.; FUJIFILM Diosynth Biotechnologies Corporation; Celltrion Inc.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is one of the major growth drivers for the CAR-T cellular immunotherapy drug market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in the U.S. in 2017 and around 600,920 people will die from this disease. This growing prevalence of cancer is expected to drive demand for CAR-T cellular immunotherapy drugs in the coming years.
- Rising awareness about CAR-T cellular immunotherapy drugs: The rising awareness about CAR-T cellular immunotherapy drugs among patients and healthcare professionals is another key factor driving growth of this market. There has been an increase in number of clinical trials being conducted on these drugs which has helped raise awareness about their potential benefits among patients and doctors alike. This is likely to boost adoption rates for these therapies in the coming years
Scope Of The Report
Report Attributes
Report Details
Report Title
CAR-T Cellular Immunotherapy Drug Market Research Report
By Type
CD19-Targeted, BCMA-Targeted
By Application
Multiple Myeloma, Non-Hodgkin lymphoma, Leukemia
By Companies
Novartis AG, Kite Pharma, Bristol Myers Squibb, Fosun Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
199
Number of Tables & Figures
140
Customization Available
Yes, the report can be customized as per your need.
Global CAR-T Cellular Immunotherapy Drug Market Report Segments:
The global CAR-T Cellular Immunotherapy Drug market is segmented on the basis of:
Types
CD19-Targeted, BCMA-Targeted
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Multiple Myeloma, Non-Hodgkin lymphoma, Leukemia
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis AG
- Kite Pharma
- Bristol Myers Squibb
- Fosun Pharma
Highlights of The CAR-T Cellular Immunotherapy Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- CD19-Targeted
- BCMA-Targeted
- By Application:
- Multiple Myeloma
- Non-Hodgkin lymphoma
- Leukemia
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the CAR-T Cellular Immunotherapy Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
CAR-T cellular immunotherapy drugs are a type of cancer treatment that use the patientu2019s own immune system to fight cancer. CAR-T cells are genetically modified T cells that have been specifically engineered to recognize and attack specific types of cancer.
Some of the key players operating in the car-t cellular immunotherapy drug market are Novartis AG, Kite Pharma, Bristol Myers Squibb, Fosun Pharma.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 CAR-T Cellular Immunotherapy Drug Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 CAR-T Cellular Immunotherapy Drug Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 CAR-T Cellular Immunotherapy Drug Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the CAR-T Cellular Immunotherapy Drug Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global CAR-T Cellular Immunotherapy Drug Market Size & Forecast, 2018-2028 4.5.1 CAR-T Cellular Immunotherapy Drug Market Size and Y-o-Y Growth 4.5.2 CAR-T Cellular Immunotherapy Drug Market Absolute $ Opportunity
Chapter 5 Global CAR-T Cellular Immunotherapy Drug Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 CAR-T Cellular Immunotherapy Drug Market Size Forecast by Type
5.2.1 CD19-Targeted
5.2.2 BCMA-Targeted
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global CAR-T Cellular Immunotherapy Drug Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 CAR-T Cellular Immunotherapy Drug Market Size Forecast by Applications
6.2.1 Multiple Myeloma
6.2.2 Non-Hodgkin lymphoma
6.2.3 Leukemia
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global CAR-T Cellular Immunotherapy Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 CAR-T Cellular Immunotherapy Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America CAR-T Cellular Immunotherapy Drug Analysis and Forecast
9.1 Introduction
9.2 North America CAR-T Cellular Immunotherapy Drug Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America CAR-T Cellular Immunotherapy Drug Market Size Forecast by Type
9.6.1 CD19-Targeted
9.6.2 BCMA-Targeted
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America CAR-T Cellular Immunotherapy Drug Market Size Forecast by Applications
9.10.1 Multiple Myeloma
9.10.2 Non-Hodgkin lymphoma
9.10.3 Leukemia
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe CAR-T Cellular Immunotherapy Drug Analysis and Forecast
10.1 Introduction
10.2 Europe CAR-T Cellular Immunotherapy Drug Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe CAR-T Cellular Immunotherapy Drug Market Size Forecast by Type
10.6.1 CD19-Targeted
10.6.2 BCMA-Targeted
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe CAR-T Cellular Immunotherapy Drug Market Size Forecast by Applications
10.10.1 Multiple Myeloma
10.10.2 Non-Hodgkin lymphoma
10.10.3 Leukemia
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific CAR-T Cellular Immunotherapy Drug Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific CAR-T Cellular Immunotherapy Drug Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific CAR-T Cellular Immunotherapy Drug Market Size Forecast by Type
11.6.1 CD19-Targeted
11.6.2 BCMA-Targeted
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific CAR-T Cellular Immunotherapy Drug Market Size Forecast by Applications
11.10.1 Multiple Myeloma
11.10.2 Non-Hodgkin lymphoma
11.10.3 Leukemia
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America CAR-T Cellular Immunotherapy Drug Analysis and Forecast
12.1 Introduction
12.2 Latin America CAR-T Cellular Immunotherapy Drug Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America CAR-T Cellular Immunotherapy Drug Market Size Forecast by Type
12.6.1 CD19-Targeted
12.6.2 BCMA-Targeted
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America CAR-T Cellular Immunotherapy Drug Market Size Forecast by Applications
12.10.1 Multiple Myeloma
12.10.2 Non-Hodgkin lymphoma
12.10.3 Leukemia
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) CAR-T Cellular Immunotherapy Drug Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) CAR-T Cellular Immunotherapy Drug Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) CAR-T Cellular Immunotherapy Drug Market Size Forecast by Type
13.6.1 CD19-Targeted
13.6.2 BCMA-Targeted
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) CAR-T Cellular Immunotherapy Drug Market Size Forecast by Applications
13.10.1 Multiple Myeloma
13.10.2 Non-Hodgkin lymphoma
13.10.3 Leukemia
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 CAR-T Cellular Immunotherapy Drug Market: Competitive Dashboard
14.2 Global CAR-T Cellular Immunotherapy Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis AG
14.3.2 Kite Pharma
14.3.3 Bristol Myers Squibb
14.3.4 Fosun Pharma